What are Alto Neuroscience's total assets?

Alto Neuroscience (ANRO) holds $276.3M in total assets, up 60.7% year over year.

How much debt does Alto Neuroscience have?

Alto Neuroscience carries $20.9M in total debt against $243.4M of shareholders' equity, a debt-to-equity ratio of 0.09.

How much cash does Alto Neuroscience have?

Alto Neuroscience holds $264.3M in cash and equivalents.

Can Alto Neuroscience cover its short-term obligations?

Its current ratio is 20.52 — current assets exceed current liabilities.

Where does Alto Neuroscience's balance sheet data come from?

Every line is extracted from Alto Neuroscience's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Alto Neuroscience ANRO Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23
Cash and cash equivalents	$176.98M+4.9%	$168.73M+104%	$82.55M+70.8%
Restricted cash	$500K0.0%	$500K—	$0—
Prepaid expenses and other current assets	$7.9M+3.4%	$7.64M+154%	$3M—
Total current assets	$177.72M+4.9%	$169.34M+98.3%	$85.39M—
Property and equipment, net	$1.87M-29.8%	$2.67M+141%	$1.11M—
Accumulated depreciation	$1.53M+52.0%	$1M+46.8%	$684K—
Operating lease right-of-use assets	$4.26M-15.4%	$5.04M—	$0—
Other non-current assets	$338K+8,350%	$4K-96.9%	$131K—
Total assets	$184.69M+4.0%	$177.54M+105%	$86.63M—
Accounts payable	$6.99M-13.5%	$8.09M+561%	$1.22M—
Accrued expenses	$4.87M-42.2%	$8.43M+85.8%	$4.54M—
Current portion of long-term debt	$585K—	$0—	$0—
Operating lease liabilities, current	$1.15M+32.3%	$870K+596%	$125K—
Accrued interest	$118K+51.3%	$78K-7.1%	$84K—
Total current liabilities	$11.33M+13.2%	$10.01M+78.4%	$5.61M—
Long-term debt	$16.17M+57.7%	$10.25M+4.0%	$9.86M—
Operating lease liabilities, non-current	$3.82M-15.3%	$4.52M—	$0—
Total liabilities	$33.55M+28.6%	$26.08M+55.0%	$16.82M—
Common stock	$3K0.0%	$3K—	$0—
Additional paid-in capital	$352.75M+21.7%	$289.95M+5,298%	$5.37M—
Retained earnings	-$201.63M-45.7%	-$138.4M-79.8%	-$76.97M—
Accumulated other comprehensive income (loss)	$22K+122%	-$101K-27.8%	-$79K—
Total stockholders' equity	$151.14M-0.2%	$151.46M+311%	-$71.67M-86.6%
Total liabilities and stockholders' equity	$184.69M+4.0%	$177.54M+105%	$86.63M—
Net Investment in Lease	$4.26M-15.4%	$5.04M—	$0—
Operating lease right-of-use assets	$4.26M-15.4%	$5.04M—	$0—
Other Assets	$338K+8,350%	$4K-96.9%	$131K—
Operating Lease Right-of-Use Assets in Other Assets	$4.26M-15.4%	$5.04M—	$0—
Accrued Manufacturing Costs	$4.87M-1.6%	$4.95M+856%	$518K—
Other Commercial Liabilities	$8.86M+5.1%	$8.43M+85.8%	$4.54M—
Convertible Debt - Current	$2.23M+70.8%	$1.3M—	$0-100%
Accrued Liabilities, Current	$8.86M+5.1%	$8.43M+85.8%	$4.54M—
Compensation and benefits	$4.87M-1.6%	$4.95M+856%	$518K—
Total debt	$21.73M+38.9%	$15.64M+56.6%	$9.99M—
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.00—
Common Stock Shares Authorized	——	——	——
Common Stock Shares Issued	31.9M+18.3%	27M+604%	3.8M—
Convertible Preferred Stock Authorized Shares	——	——	——
Convertible Preferred Stock Issued Shares	——	——	——
Convertible Preferred Stock Outstanding Shares	——	——	——
Preferred Stock Par Value Per Share	——	——	——
Share-Based Payment - Unrecognized Cost of Nonvested Awards	——	——	——
Shares Reserved for Future Issuance Under Stock Plans	11.2M+117%	5.1M-70.8%	17.6M—
Weighted Average Exercise Price of Outstanding Options	——	——	——
Fair Value Measurement Disclosure	$2.23M+70.8%	$1.3M-3.6%	$1.35M—
Accrued research	$2.12M+30.7%	$1.63M-30.2%	$2.33M—
Common stock, capital shares reserved for future issuance	$11.15M+117%	$5.14M-70.8%	$17.63M—
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$0—
Common stock, shares authorized (in shares)	$500M0.0%	$500M+862%	$52M—
Common stock, shares issued (in shares)	$31.92M+18.3%	$26.99M+604%	$3.83M—
Common Stock, Shares, Outstanding	$31.92M+18.3%	$26.99M+604%	$3.83M—
Convertible Debt	$2.23M+70.8%	$1.3M—	$0—
Convertible Debt Fair Value Disclosures	$2.23M+70.8%	$1.3M—	——
Cost not yet recognized	——	——	——
Number of clinical-stage assets	——	——	——
Number of wholly owned subsidiaries	——	——	——
Other accrued liabilities	$599K-33.8%	$905K+75.7%	$515K—
Preferred Stock, Par or Stated Value Per Share	——	——	——
Preferred Stock, Shares Authorized	——	——	——
Preferred Stock, Shares Issued	——	——	——
Preferred Stock, Shares Outstanding	——	——	——
Prepaid expenses	$1.04M+11.9%	$932K+78.5%	$522K—
Prepaid Insurance	$191K+8.5%	$176K—	$0—
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Alto Neuroscience's total assets?: Alto Neuroscience (ANRO) holds $276.3M in total assets, up 60.7% year over year.
How much debt does Alto Neuroscience have?: Alto Neuroscience carries $20.9M in total debt against $243.4M of shareholders' equity, a debt-to-equity ratio of 0.09.
How much cash does Alto Neuroscience have?: Alto Neuroscience holds $264.3M in cash and equivalents.
Can Alto Neuroscience cover its short-term obligations?: Its current ratio is 20.52 — current assets exceed current liabilities.
Where does Alto Neuroscience's balance sheet data come from?: Every line is extracted from Alto Neuroscience's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.